Zacks Research Issues Negative Outlook for ALLO Earnings

Allogene Therapeutics, Inc. (NASDAQ:ALLO) – Equities research analysts at Zacks Research decreased their Q2 2025 earnings per share (EPS) estimates for Allogene Therapeutics in a note issued to investors on Thursday, January 9th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of ($0.38) for the quarter, down from their previous forecast of ($0.37). The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($1.27) per share. Zacks Research also issued estimates for Allogene Therapeutics’ Q3 2025 earnings at ($0.40) EPS, Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($1.57) EPS, Q1 2026 earnings at ($0.40) EPS, Q2 2026 earnings at ($0.43) EPS, Q3 2026 earnings at ($0.45) EPS, Q4 2026 earnings at ($0.47) EPS and FY2026 earnings at ($1.75) EPS.

Other equities research analysts also recently issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price target on shares of Allogene Therapeutics in a research note on Friday, November 8th. Piper Sandler reduced their price objective on shares of Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. Finally, William Blair restated an “outperform” rating on shares of Allogene Therapeutics in a report on Thursday, November 14th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, Allogene Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $9.73.

Allogene Therapeutics Stock Performance

Allogene Therapeutics stock opened at $1.92 on Monday. The stock’s 50 day moving average price is $2.30 and its two-hundred day moving average price is $2.53. The stock has a market capitalization of $402.57 million, a price-to-earnings ratio of -1.23 and a beta of 0.86. Allogene Therapeutics has a 52-week low of $1.78 and a 52-week high of $5.78.

Institutional Investors Weigh In On Allogene Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ALLO. Federated Hermes Inc. purchased a new position in Allogene Therapeutics in the second quarter worth $29,000. Private Advisor Group LLC bought a new stake in shares of Allogene Therapeutics during the 3rd quarter worth $34,000. Algert Global LLC bought a new position in Allogene Therapeutics during the second quarter valued at about $35,000. MML Investors Services LLC purchased a new stake in Allogene Therapeutics during the third quarter worth about $56,000. Finally, AQR Capital Management LLC bought a new position in shares of Allogene Therapeutics during the 2nd quarter valued at approximately $64,000. 83.63% of the stock is owned by institutional investors.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).